Neoantigen × AI
Daily research signal
№54Brief

Evaxion EVX-01 durability holds; audit flags LLM neoantigen shortcuts

Today pairs a durability readout with a caution on evaluation rigor.

Evaxion's three-year Phase II data for its AI-designed personalized vaccine EVX-01 show maintained responses in advanced melanoma, the kind of follow-up that supports platform credibility.The Pharma Letter On the methods side, a new audit of agentic LLMs applied to TCR-pMHC binding shows how tool-trace shortcuts can fake biological reasoning, a direct warning for teams using LLM pipelines in neoantigen prediction.arXiv

2new stories
ClinicalyesterdayNew

Positive Phase II trial with Evaxion’s personalized cancer vaccine EVX-01 - The Pharma Letter

Evaxion (Nasdaq: EVAX) reported three-year follow-up from its Phase II trial of personalized cancer vaccine EVX-01 in advanced melanoma: all patients maintained the clinical responses observed at two years, with no tumor progression, and received EVX-01 as stand-alone therapy in the third year. Shares rose 5.5% to $2.99 in pre-market trading on the news. For a techbio whose vaccines come off its AI-Immunology platform, extended response durability without progression is the key evidence point that its AI-selected antigens translate into lasting clinical benefit, and stand-alone activity in year three strengthens the case beyond earlier-trial contexts.

news · yesterday · The Pharma Letter

01

01
AI / Methods2 days agoNew

Auditing Tool Traces in Agentic LLMs: Source Localization and Counterfactual Dependence Testing

A methods paper introduces a two-stage audit for agentic LLM pipelines: Per-Tool TF-IDF Decomposition (PT2D) localizes label-predictive patterns to individual tool results, and Token-Class Redaction counterfactually tests whether the model actually depends on them. Applied to TCR-pMHC binding, tool augmentation initially looked like it beat a no-evidence baseline, but the audit traced the signal to identifiers in one tool result, and redacting them dropped performance to chance. Since TCR-pMHC prediction underpins neoantigen prioritization, this is a concrete warning that shortcut-driven gains can masquerade as biological reasoning in LLM-based discovery workflows, and an actionable template for auditing them before such results inform vaccine design or diligence claims.

arxiv · 2 days ago · Junhao Liu, Tianxiao Li, Yongxian Wu, Ziheng Duan, Ren Li, Jing Zhang, Martin Renqiang Min